OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial Board	425
Adenosine receptor signalling as a driver of pulmonary fibrosis	413
Inflammation, lipids, and pain in vulvar disease	348
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	281
Matrikines in the skin: Origin, effects, and therapeutic potential	271
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	233
Collateral lethality: A unique type of synthetic lethality in cancers	211
Treatment approaches for alcohol use disorder with metabolic dysfunction	199
SGLT2 inhibitors: Do they have antiarrhythmic properties?	187
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	165
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	151
The role of macrophages in asthma-related fibrosis and remodelling	122
Non-canonical G protein signaling	119
Endothelial dysfunction as a complication of anti-cancer therapy	117
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	114
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	110
Potential neonatal toxicity of new psychoactive substances	110
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	110
Treatment strategies for leptomeningeal disease in patients with breast cancer	108
Unfolded protein responses: Dynamic machinery in wound healing	107
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	106
TAAR1 as an emerging target for the treatment of psychiatric disorders	105
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	103
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	99
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	94

Management of drug-resistant hypertension as a heterogeneous disorder	88
Boron in cancer therapeutics: An overview	86
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	86
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	85
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	85
Editorial Board	84
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	82
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	82
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	81
Dysregulation of metabolic pathways in pulmonary fibrosis	80
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	78
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	78
Editorial Board	76
Editorial Board	74
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	74
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	73
PGRMC1: An enigmatic heme-binding protein	73
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	73
Bispecific antibodies for the treatment of neuroblastoma	72
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	71
Review: Sex-related differences in the treatment of cardiac arrhythmia	70
Pharmacological treatment of cardiogenic shock – A state of the art review	70
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	68
Natural products that alleviate depression: The putative role of autophagy	68
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	67
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	67
DNA methylation in cell plasticity and malignant transformation in liver diseases	66
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	66
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	66
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	65
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	63
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	62
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	61
Insights into effective protocol structuring: optimizing dosing strategies, experimental design, and statistical approaches	61
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	61